Fusion proteins for prodrug activation

Details Fusion proteins for prodrug activation Fusion proteins for prodrug activation

2006-06-13

2006-06-13

Saunders, David (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of culturing cells in suspension

C424S134100, C424S135100, C424S137100, C424S155100, C424S178100, C424S182100, C435S069700, C435S252330, C435S254200, C435S254210, C530S387500, C530S388500, C530S391100

Reexamination Certificate

active

07060495

ABSTRACT:
The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.

REFERENCES:
patent: 4870009 (1989-09-01), Evans et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 6248516 (2001-06-01), Winter et al.
patent: 6258360 (2001-07-01), von Borstel et al.
patent: 2019559 (1990-12-01), None
patent: A 2062047 (1992-08-01), None
patent: 0302473 (1989-02-01), None
patent: 0361908 (1990-04-01), None
patent: 0382411 (1990-08-01), None
patent: 0392745 (1990-10-01), None
patent: 0404097 (1990-12-01), None
patent: 0501215 (1992-09-01), None
patent: WO 88/07378 (1988-10-01), None
patent: WO 89 10140 (1989-11-01), None
patent: WO 91/00108 (1991-01-01), None
patent: WO 91/08770 (1991-06-01), None
patent: WO 91/11201 (1991-08-01), None
patent: 9313805 (1993-07-01), None
Ong et al, Cancer Research, 51, 1619-1626, 1991.
Huston et al, Methods in Enzthology, 203, 46-89, 1991.
I. Hellstrom et al., “Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas,” Proc. Natl. Acad. Sci. USA, vol. 83, pp. 7059-7063 (1986).
I. Hellstrom et al., “Monoclonal mouse antibodies raised against human lung carcinoma,” Cancer Res, vol. 46, No. 8, pp. 3917-3923 (1986).
C. A. Janeway, Jr., et al., “Immuno Biology The Immune System in Health and Disease,” Current Biology Ltd/Garland Publishing Inc., New York, pp. 12:33-12:36 (1994).
Perham, R.N., “Domains, Motifs, and Linkers in 2-Oxo Acid Dehydrogenase Multienzyme Complexis: A Paradigm in the Design of a Multifunctional Protein.”Biochemistry, 30:8501-8512, 1991.
Fremont, D.H., et al., “Biophysical Studies of T-cell receptors and Their Ligands.”Curr. Opin. Immunol., 8:93-100, 1996.
Brocklehurst, S., “Re: Linker Peptide in Two-domain fusion Protein,” [http://www.bio.net//hypermail/protein-analysis/proteins. 199307/0048.html], Jul. 26, 1993.
Osband, Immunol. Today, 11(6): 193-195, 1990.
Chatterjee, Cancer Immunol. Immunother., 38:75-82.
Curti, Crit. Rev. Oncol. Hematol., 14:29-39, 1993.
Jain, Sci, America, 271(1):58-63, 1994.
Kerr, D.E., et al., “Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide”, Cancer Immuno. Immunother, vol. 31: 202-206 (1990).
Florent, J.C. et al., “N-(-D-Glycopyranosyl)-Benzyloxycarbonyl Daunorubicine Pro-Prodrugs Synthesis and enzymatic behaviour”, inst. Carbohydr. Symp. Paris, A262, p. 297 (1992).
Andrianomenjanahary, S. et al., “N-(-D-Glycopyranosyl)-Chlorobenzyloxycarbonyl Daunorubicine Pro-Prodrugs and their enzymatic cleavage”, Inst. Carbohydro. Symposium Paris, A264, p. 299 (1992).
Goochee, C.F. et al., “The Oligosaccharides of Glycoproteins; Bioprocess Factors Affecting Oligosaccharide Structure and Their Effect on Glycoprotein Properties”, Biotechnology, vol. 9:1347-1355 (1991).
Gussow, D. et al., “Humanization of Monoclonal Antibodies”, Methods in Enzymology, vol. 203:99-121 (1991).
Jefferson, R.A. et al., “B-Glucuronidase fromEscherichia colias a gene-fusion marker”, Proc. Natl. Acad. Sci. USA, vol. 83: 8447-8451 (1986).
Hussain, M. et al., “Cloning and Sequencing of the Metallothioprotein B-Lactamase II Gene ofBacillus cereus569/H inEscherichia coli”, Journal of Bacteriology, vol. 164:22-229 (1985).
Sharma, S.K. et al., “Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model”, Br. J. Cancer, vol. 61: 659-662 (1990).
Bosslet, K. et al., “Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation,” British Journal of Cancer, 65(2): 234-238 (1992).
Brinkmann, Ulrich et al., “Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: Influence of interdomain connections,” Proceedings of the National Academy of Sciences of the USA, 89(7): 3075-3079 (1992).
Kappel, C. et al. (1992). Current Opinion: Biotechnology, 3:548-53.
Shamay, A. et al. (1991) J. Animal Science, 69: 4552-62.
Borden, T. et al. (1991) Mechanisms of Development, 36: 67-74.

Affiliated with

Also associated with

Rating

Fusion proteins for prodrug activation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion proteins for prodrug activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins for prodrug activation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3672777